TCR2 Therapeutics to Present New Data from its TRuC™ T Cell Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Tuesday, October 31, 2017 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

CAMBRIDGE, Mass., Oct. 31, 2017 /PRNewswire/ -- TCR2 Therapeutics Inc. announced today that new preclinical data

from two of its TRuC™ programs will be highlighted at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting to be held November 8-12, 2017 in National Harbor, Maryland.
This includes the lead solid tumor program TC-210 targeting mesothelin that will enter the clinic in 2018.

"We look forward to presenting new data from our TRuC™ programs as they continue to demonstrate robust efficacy, persistence and potential safety benefits in treating solid tumors. We will also share mechanistic data that further validate our approach is truly differentiated from existing CAR or TCR therapies as the first platform to engage the entire T cell receptor complex without HLA restriction," said Robert Hofmeister, PhD, Chief Scientific Officer. "It is an exciting time for TCR2 as we advance our TC-210 solid tumor program into the clinic in 2018 and expand our pipeline using TRuC™ technology against several other targets."

The schedule for TCR2's poster presentations is as follows:

Title: Preclinical Evaluation of Mesothelin-Specific T Cell Receptor Fusion Constructs (TRuC™) Approach Utilizing the Signaling Power of the Complete TCR Complex: A New Opportunity for Solid Tumor TherapyPoster Number: P171Date & Time: Friday, November 10, 2017 12:30-2:00pm and 6:30-8:00pm ESTPresenter: Jian Ding, PhD, Senior Scientist, TCR2 Therapeutics

Title: TRuC™-T Cells: A Novel Class of Engineered T Cells that Power T Cells Through the Entire T Cell Receptor Complex without MHC RestrictionPoster Number: P193Date & Time: Friday, November 10, 2017 12:30-2:00pm and 6:30-8:00pm ESTPresenter:  Ekta Patel, PhD, Senior Scientist, TCR2 Therapeutics

About TCR2 Therapeutics

TCR2 Therapeutics is an immuno-oncology company that has pioneered a novel class of T cell therapies for solid tumors that utilize the full signaling power of complete T cell receptors (TCR). TCR2 has developed a unique proprietary TRuC™ platform which can reprogram the natural TCR complex to elicit rapid killing of cancer cells with persistence and low cytokine release. The company has demonstrated superior activity against several tumor targets in preclinical models compared to CAR T cells and will advance its lead program TC-210 into the clinic in 2018. TCR2 was founded in 2015 by Dr. Patrick Baeuerle and backed with a $44.5M Series A financing led by MPM Capital and F2 Ventures. It has since assembled a world-class team of immunotherapy experts and entrepreneurs located in the heart of Kendall Square in Cambridge, MA. For more information, please visit


View original content:

SOURCE TCR2 Therapeutics

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store